Clinical Trials
44
Trial Phases
4 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (42 trials with phase data)β’ Click on a phase to view related trials
Expanded Access Program (EAP) Designed to Provide Access to Botensilimab and Balstilimab Before Regulatory Approval
- Conditions
- Colorectal Cancer (CRC)Pancreatic CancerNon-Small Cell Lung Cancer (NSCLC)Hepatocellular Carcinoma (HCC)MelanomaSarcomaOvarian CancerProstate Cancer
- First Posted Date
- 2024-12-30
- Last Posted Date
- 2024-12-30
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT06751524
A Study of Botensilimab in Participants With Metastatic Pancreatic Cancer
- Conditions
- Metastatic Pancreatic Ductal Adenocarcinoma
- Interventions
- First Posted Date
- 2022-11-29
- Last Posted Date
- 2025-02-17
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 81
- Registration Number
- NCT05630183
- Locations
- πΊπΈ
HonorHealth, Scottsdale, Arizona, United States
πΊπΈUSC Norris Comprehensive Cancer Center, Los Angeles, California, United States
πΊπΈUSC Norris Oncology, Newport Beach, California, United States
A Study of Botensilimab and Balstilimab for the Treatment of Colorectal Cancer
- Conditions
- Metastatic Colorectal Cancer
- Interventions
- First Posted Date
- 2022-11-08
- Last Posted Date
- 2025-09-04
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 234
- Registration Number
- NCT05608044
- Locations
- πΊπΈ
HonorHealth Research Institute, Scottsdale, Arizona, United States
πΊπΈCity of Hope National Medical Center, Duarte, California, United States
πΊπΈKeck School of Medicine of the University of Southern California, Los Angeles, California, United States
Expanded Access for Cancer Treatment With Balstilimab (AGEN2034) and Zalifrelimab (AGEN1884)
- Conditions
- Cancer
- First Posted Date
- 2022-10-10
- Last Posted Date
- 2025-04-30
- Lead Sponsor
- Agenus Inc.
- Registration Number
- NCT05572970
- Locations
- πΊπΈ
University of Alabama at Birmingham, Birmingham, Alabama, United States
πΊπΈArizona Oncology Associates, Tucson, Arizona, United States
πΊπΈHoag Gynecologic Oncology, Newport Beach, California, United States
A Study of Botensilimab (AGEN1181) for the Treatment of Advanced Melanoma
- Conditions
- Advanced Melanoma
- Interventions
- First Posted Date
- 2022-09-07
- Last Posted Date
- 2025-03-10
- Lead Sponsor
- Agenus Inc.
- Target Recruit Count
- 174
- Registration Number
- NCT05529316
- Locations
- π·πΊ
Blokhin National Medical Research Oncology Centre, Moscow, Russian Federation
π·πΊMoscow City Oncology Hospital #62, Moscow, Russian Federation
πΊπΈScottsdale Healthcare Hospitals DBA HonorHealth, Scottsdale, Arizona, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- Next
News
Breakthrough Immunotherapy Combination Shows Promise Against Common Colorectal Cancer in Phase 1 Trial
A phase 1 trial of 148 patients demonstrated that the combination of botensilimab and balstilimab immunotherapy drugs successfully treated microsatellite stable metastatic colorectal cancer, the most common form that has historically not responded to immunotherapy.